The document describes TSRL Inc.'s Technology Accelerator program, which aims to help move therapeutic assets past the "Valley of Death" by providing infrastructure, scientific and business resources, and funding to drive projects from pre-clinical development to an Investigational New Drug application. The accelerator selects potential drug candidates based on criteria to maximize commercialization potential and provides services like project management, drug development expertise, and access to networks to help obtain funding and partners. The goal is to generate necessary data packages and commercialization plans to support projects reaching their next development milestones.

1. NON-CONFIDENTIAL
Driving Value from Lead to Clinic
TSRL, Inc. Technology Accelerator
Drew Hertig, MBA
Business Development
ahertig@tsrlinc.com
A New Model for Preclinical Drug Development
1bd@tsrlinc.com  734-663-3607  www.tsrlinc.com

2. NON-CONFIDENTIAL
The Challenge
Many therapeutic assets are struggling to find funding to move past the “Valley of Death”
Inception Pre-lead Lead IND NDA
3-5 years 1 year 2 years 5 years
ValueofOpportunity
Development Timeline“Valley of Death”
Value Infection
Drug
Discovery
10k-30k
Lead
Selection
30-60
Preclinical
Development
10-20
Phase I
5-10
Phase II
2-5
Phase III
2
Approval
1
©2015 TSRL, Inc.
2

3. NON-CONFIDENTIAL
The Opportunity
Academic life science drug products require…
• Collaboration: Strong interdisciplinary science & business acumen
• Visibility: Industry is increasingly looking for academia for new products
• Relationships: NIH is emerging as a strong player in translational medicine
Funding climate for early stage assets changing
• VC funds have moved to later stage assets
• Government and foundations are increasingly stepping in with funding
• Commercial potential is not sufficiently analyzed
• Comprehensive data package demonstrating drug product potential is lacking
3

4. NON-CONFIDENTIAL
TSRL, Inc. Accelerator Model:
A hybrid model leveraging minimally-dilutive funding and experienced
pharma management to “de-risk” and drive projects to IND
4

5. NON-CONFIDENTIAL
Our Accelerator Strategy…
• Builds on our proven track record of designing and developing oral and
targeted drugs, with an initial focus on infectious diseases
• Develops drug assets in-house or in-licensed from academic and industry
organizations
• Selects potential drug assets against a set of criteria established to maximize
the potential for commercialization success
• Provides infrastructure, laboratory, scientific and business resources, as well
as in-kind services to drive projects to IND
5

6. NON-CONFIDENTIAL
Incubator vs Accelerator: What’s the Difference?
Working Space: Business incubators typically provide office and/or wet-lab
space, with the opportunity for entrepreneurs to mingle with each other
• Commercialization strategy assistance
• Access to high-level networks
• Flexibility to expand as company grows
JLabs, Janssen Labs innovation center, an incubator
“Nesting” Company: Accelerators offer additional
services, i.e. human capital and seed funding:
• All of the above services, plus
• Equipment/comprehensive preclinical research
services
• Seed funding in exchange for an equity stake in a
future NewCo
http://www.oxbridgebiotech.com/review/business-development/incubator-vs-accelerator-whats-difference/ 6

7. NON-CONFIDENTIAL
TSRL TA Value-Add Model
• Develop plan/budget
• Generate data and drive
project to IND or POC
• Nourish partnerships and
collaborations
• GOAL: Obtain total data
package and refined comm
plan for next inflection point
1) The Idea
• Inventor/Entrepreneur
• Drug Therapy Concepts
• Intellectual Property
2) Screening
• Devise/evaluate concepts
for technical do-ability
• Analyze & uncover
commercial potential
• GOAL: Submit SBIR grant
with high likelihood of
success
4) Development
5) Decision
• No-go decision results in
feedback, development
plan, data package
• Go decision results in TSRL
Inc. partnership, NewCo,
external investment,
acquisition or out-license
• GOAL: Obtain ROI of 5-10x
per asset
Value of Project
ResourcesRequired
Pipeline Discovery
Preclinical Development
3) Go/No-Go
©2015 TSRL, Inc.
7

8. NON-CONFIDENTIAL
9 Grants/Yr.
Pipeline Discovery
Technology Disclosure
• Source from referrals, internal projects,
conferences, inbound and outbound websites,
through Accelerator RFPs
Technology Assessment & Rubric
• Prepare with Commercial Assessment (CA) and
Project Summary Document (PSD)
SBIR Grant Selection
• Select the best projects from a combination of
“fundability” and adherence to core portfolio
120 Disclosures/Yr.
15 Assessments/Yr.
8

9. NON-CONFIDENTIAL
Consultants
Infrastructure & Expertise
9
Wet Labs
Animal Labs
Grant Writing
Fundraising
Drug Development
Project Management
Oral Drug Delivery
Prodrug Science
Strategic Partners NIH / FDA
CROs
TSRL TA Team
& Collaborators

10. NON-CONFIDENTIAL
Technology Accelerator
Project
C
Project
B
Project
A
Funding
• Prior funding
• Stage/level of funding
Science
• Expertise-fit
• Development risk
• Feasibility
Intellectual Property
• Strength of IP
• Prior art
• Scope
Commercial Potential
• Market size
• Reimbursement
• Development costs
• Competitive landscape
Business Structure
• Licensing (inventor
equity)
• Risk-adjusted portfolio
• Business formation
Commercial Assessment
People
• Inventor credibility,
network, and business
acumen
• Management skill and
track record
Product
• Clinical path
• Time to market
• Manufacturing
10

11. NON-CONFIDENTIAL
We Are Looking to Collaborate With…
• Life science entrepreneurs seeking to commercialize their early stage
drug therapy concepts
• In need of support for:
• Drug development expertise – drug delivery and PK/PD core
• Minimally dilutive funding
• Commercialization assessment
• Infrastructure capabilities for generating crucial preliminary data
• Admin/business operations support
….and who are time-constrained and welcome a collaborative
partner to expedite their drug product development
11

12. NON-CONFIDENTIAL
Consideration in Return
• Collaborative Research and Development Agreement as your first
industry partner
• ≥50% of grant-specific aims performed at TSRL, Inc. laboratories or
within our network
• Equity consideration upon exit
• First right-of-refusal
• Non-royalty/sublicense consideration
Our TA team works as collaborators on your project—
as a result, we have a vested interest in your success
12

13. NON-CONFIDENTIAL
Summary
• TSRL Inc. Technology Accelerator provides life science entrepreneurs with:
• Infrastructure » office & bench space, AAALAC-accredited animal facilities, BSL-2,
radiation safety license, controlled substance license
• Laboratory services » equipment, SOPs, QC
• Scientific resources » in-kind services, development/research strategy support
• Business resources » administrative, commercialization plan support, business
development, marketing
• Experience » analytical chemistry, animal models, PK/ADME, drug delivery,
regulatory (FDA/Pre-IND), industry management experience
• Network » collaborators, partners, consultants, relationships (NIH)
Our mission is to provide investigators with means to bridge the “Valley of Death” and
to advance potentially life-saving drug products
13

14. NON-CONFIDENTIAL
Questions?
Thank You!
14